Qureator

Biotechnology, 7094 Miratech Dr, San Diego, California, 92121, United States, 11-50 Employees

Phone Number: +82********

Who is QUREATOR

Qureators Microphysiological Systems (MPS) known as Curiochips, are designed for recapitulating the complexity of tissue microenvironments, thus providing ideal microscale 3D cell culture...

Get Full Access

Headquarters: 7094 Miratech Dr, San Diego, California, 92121, United States
Date Founded: 2017
Employees: 11-50
Revenue: Under $1 Million
Active Tech Stack: See technologies

Industry: Biotechnology

SIC Code: 8712

Does something look wrong? Fix it. | View contact records from QUREATOR

Qureator Org Chart and Mapping

Employees

Sehee Jung

Business Development Assistant

Email
Phone

Byungjun Lee

Senior Staff Engineer

Email
Phone

See Full Org Chart

View Email Formats for Qureator

You are signed out

Join Now

Free credits every month

Frequently Asked Questions Regarding Qureator

Answer: Qureator's headquarters are located at 7094 Miratech Dr, San Diego, California, 92121, United States

Answer: Qureators Microphysiological Systems (MPS) known as Curiochips, are designed for recapitulating the complexity of tissue microenvironments, thus providing ideal microscale 3D cell culture conditions. The company was formerly known as Curiochips and changed its name to Qureator in 2020. Qureator is headquartered in San Diego, California. Qureator, a biomedical company, focuses on the development of novel platforms and high-throughput disease models for precision medicine in areas of high unmet medical needs. The company provides Microphysiological Systems (MPS) which enable investigators to perform co-cultures of multiple cell types in 3D and high-throughput screenings for biomedical research and drug discovery. The company also offers a variety of patient-derived in vitro models in organs-on-chips which closely recapitulate the pathophysiology of diseases. These models can be efficiently applicable to target identification and compound screening, especially in the areas of fibrosis, oncology, angiogenesis, ocular disease and vasculogenesis. The company has multiple collaborations with pharmaceutical companies and academic institutions for assay development, safety evaluation, and drug discovery. Conventional preclinical testing has faced a problem in that the results do not correctly reflect and anticipate the drug effect on the human body, which results in significantly increased cost and time of drug discovery and development. Academia and industries have endeavored to solve this mismatched preclinical testing for human drug treatments over the last several decades. As a result, several in vitro testing platforms such as 3D cell culture, organoid, bioprinting, Microphysiological Systems (MPS) and Organ-on-a-Chip technologies have been developed. Although these approaches have comparative advantages toward specific purposes, we concluded that the Organ-on-a-Chip technology is the most appropriate one to mimic human model systems and evaluate drug candidates.